Genovese Burford & Brothers Wealth & Retirement Plan Management’s Teva Pharmaceuticals TEVA Stock Holding History

Genovese Burford & Brothers Wealth & Retirement Plan Management’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-345	Closed	-$8K	–	341
2018 Q2	$8K	Hold	345	–	–	﹤0.01%	333
2018 Q1	$6K	Buy	+345	New	+$6.74K	﹤0.01%	358
2017 Q4	–	Sell	-345	Closed	-$6K	–	430
2017 Q3	$6K	Sell	345 -411	-54%	-$9.25K	﹤0.01%	321
2017 Q2	$25K	Hold	756	–	–	0.01%	194
2017 Q1	$25K	Sell	756 -104	-12%	-$3.55K	0.01%	208
2016 Q4	$32K	Hold	860	–	–	0.01%	202
2016 Q3	$39K	Hold	860	–	–	0.02%	177
2016 Q2	$43K	Buy	860 +104	+14%	+$5.54K	0.02%	159
2016 Q1	$40K	Hold	756	–	–	0.02%	153
2015 Q4	$50K	Buy	+756	New	+$46.7K	0.02%	129

Other funds holding TEVA

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Berkshire Hathaway Omaha, Nebraska $263B AUM 16.68% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

ACM

Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return

HCM

Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Genovese Burford & Brothers Wealth & Retirement Plan Management's TEVA Position: Q3 2018 in Review

Genovese Burford & Brothers Wealth & Retirement Plan Management sold out of Teva Pharmaceuticals (TEVA) in Q3 2018, closing a stake of 345 shares — an estimated $8K sold.

Genovese Burford & Brothers Wealth & Retirement Plan Management first reported a position in TEVA in Q4 2015 and held it in 10 quarters. The position peaked at $50K in Q4 2015. 557 funds tracked by Wall St. Rank hold TEVA as of Q3 2018.

Genovese Burford & Brothers Wealth & Retirement Plan Management reported no remaining Teva Pharmaceuticals position as of Q3 2018 after selling out during the quarter.
Genovese Burford & Brothers Wealth & Retirement Plan Management sold 345 Teva Pharmaceuticals shares in Q3 2018, an estimated $8K.
Genovese Burford & Brothers Wealth & Retirement Plan Management first reported a position in Teva Pharmaceuticals in Q4 2015 and held it in 10 quarters.
Genovese Burford & Brothers Wealth & Retirement Plan Management's Teva Pharmaceuticals position peaked at $50K in Q4 2015.
557 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q3 2018.

Based on Genovese Burford & Brothers Wealth & Retirement Plan Management's 13F filing for Q3 2018, filed 13 Nov 2018.